雄性特异性组织相容性抗原(male specific minor histompatibility antigens,H-Y抗原)是由Y染色体上的基因编码,在雄性动物细胞中普遍表达(包括胚胎和滋养层细胞)。H-Y抗原不仅能引起基因型相同的雌性动物排斥雄性组织,也能导致人白细...雄性特异性组织相容性抗原(male specific minor histompatibility antigens,H-Y抗原)是由Y染色体上的基因编码,在雄性动物细胞中普遍表达(包括胚胎和滋养层细胞)。H-Y抗原不仅能引起基因型相同的雌性动物排斥雄性组织,也能导致人白细胞抗原匹配干细胞移植术后出现移植抗宿主性疾病(GVH)。细胞毒性T淋巴细胞检测到几个不同的H-Y抗原表位,这些肽是从胞内蛋白分离出来,由主要组织相容性复合分子结合呈递在细胞表面。H-Y抗原肽与人白细胞抗原Ⅰ类和Ⅱ类分子特异结合参与免疫反应,从而影响移植结果。近年来越来越多的文献报道了H-Y抗原的相关研究,作者主要综述编码H-Y抗原的相关候选基因,并对它在疾病等方面的前景作出了一些展望。展开更多
The peptides mixture was prepared from tumor cells by freezing-thawing cells, precipitation by heating, followed by acidification of the solution. The activation and proliferation of mouse splenocytes by HSP70-peptide...The peptides mixture was prepared from tumor cells by freezing-thawing cells, precipitation by heating, followed by acidification of the solution. The activation and proliferation of mouse splenocytes by HSP70-peptide complex, formed by the binding of HSP70 and peptides in vitro, were observed, so was the specific cytotoxicity of the proliferative lymphocytes to tumor cells. The phenotypes of the proliferative lymphocytes were analyzed by a flow cytometer. BALB/c mice inoculated with H22 hepatocarcinoma cells in peritoneal cavity or hind thigh were immunized by injection with HSP70-peptides complex to observe the inhibitory effect of the immunization on tumor and lifetime of tumor-bearing mice. On the other hand, blood samples were collected from the immunized mice to check the functions of liver and kidney. The results showed that the peptides mixture from tumor cells contained tumor-specific antigen peptides which could be presented by HSP70 to activate lymphocytes in vitro, the proliferative lymphocytes were T cells which were specifically cytotoxic to tumor cells, the in vivo growth of both ascitic and solid carcinoma could be suppressed by immunization with HSP70-peptides and the lifetime of tumor-bearing mice was prolonged, the in vivo immunization with HSP70-H22-peptides had no impact on the function of mouse liver and kidney, suggesting that there was no occurrence of autoimmunity in vivo after immunization.展开更多
To investigate the inducement of cytotoxic T lym phocytes(CTL s) by antigen peptides m ixture from different leukemia cells and the cross- reaction of the m ixtures from different cell lines,antigen peptides m ixtur...To investigate the inducement of cytotoxic T lym phocytes(CTL s) by antigen peptides m ixture from different leukemia cells and the cross- reaction of the m ixtures from different cell lines,antigen peptides m ixtures were prepared from different leukemia cell lines respectively and then bound with Hsp70 in vitro.Activation and proliferation of PBMC were observed after stim u- lation with different Hsp70 - peptide complexes.The ratio of CD8+ in proliferative cells was ana- lyzed by flow cytometry.The cytotoxicity of the activated PBMC to different target cells was as- sayed.The results showed that the antigen peptides from different leukemia cell lines,bound with Hsp70 ,could activate PBMC effectively,and stimulate the activated PBMC to proliferate.The proliferative PBMC had specific cytotoxicity to corresponding leukem ia cells.CD8+ cells,account- ing for a high proportion in proliferative cells,had a specific cytotoxicity to leukemia cells from which antigen peptides were prepared,suggesting that these CD8+ cells were CTL s specific to leukemia cells.CTL s activated by Hut78- peptides or Molt4 - peptides had a significantly stronger cytotoxicity to Hut78cells,Molt4 cells and Jurkat cells than that of CTL s activated by HL - 6 0 - peptides(P<0 .0 5 ) .And the cytotoxicity of CTL s activated by Hut78/ Molt4 - peptides to Jurkat cells was significantly stronger than that of CTL s activated by either Hut78- peptides or Molt4 - peptides alone(P<0 .0 5 ) .It is concluded that antigen peptides m ixtures from leukem ia cells can induce specific antitumor CTL s.There exists cross- reactivity among antigen peptides m ixtures from different cell lines of the sam e type leukemia and more cross- reactive antigen peptides could be obtained from m ore cell lines,suggesting that antigen peptides m ixture with broad antigenic spectrum could be prepared by using multiple leukemia cell lines.展开更多
Objective: To investigate the characteristics of specific antitumor immunity induced by antigen peptides mixture from T lymphocytic leukemia cells. Method: Antigen peptides mixtures were prepared from different leuke...Objective: To investigate the characteristics of specific antitumor immunity induced by antigen peptides mixture from T lymphocytic leukemia cells. Method: Antigen peptides mixtures were prepared from different leukemia cell lines and then bound with Hsp70 in vitro. Human peripheral blood mononuclear cells (PBMC) were cultured in vitro, and activated with Hsp70-antigen peptides. The activated PBMC was cultured continuously in vitro, and used as effector cells in vitro test of cytotoxicity to different target cells. Results: The antigen peptides from different leukemia cell lines were peptides mixture and could activate PBMC effectively if they were presented by Hsp70. The activated PBMC could proliferate in the presence of IL-2 and Hsp70-antigen peptides. The proliferative PBMC had specific cytotoxicity to leukemia cells corresponding to the antigen peptides. PBMC activated by antigen peptides from T lymphocytic leukemia cell lines could effectively kill T lymphocytic leukemia cells, and the cytotoxicity of these PBMC to T lymphocytic leukemia cells was significantly stronger than that of PBMC activated by antigen peptides from other leukemia cells (P < 0.05). PBMC activated by either Hut78-peptides or Molt 4-peptides could effectively kill Jurkat cells. And the cytotoxicity of PBMC activated by Hut78/Molt-4-peptides to Jurkat cells was significantly stronger than that of PBMC activated by either Hut78-peptides or Molt-4-peptides alone (P<0.05). Conclusion: Antigen peptides mixture from T lymphocytic leukemia cell lines can induce specific cytotoxic effect to T lymphocytic leukemia cells. There exists cross-reactivity among antigen peptides mixture from different T lymphocytic leukemia cell lines. The cross-reactivity could be amplified by blending of different antigen peptides from different T lymphocytic leukemia cell lines, suggesting that it is possible to prepare broad-spectrum antigen peptide vaccine against T lymphocytic leukemia by using multiple leukemia cell lines.展开更多
文摘雄性特异性组织相容性抗原(male specific minor histompatibility antigens,H-Y抗原)是由Y染色体上的基因编码,在雄性动物细胞中普遍表达(包括胚胎和滋养层细胞)。H-Y抗原不仅能引起基因型相同的雌性动物排斥雄性组织,也能导致人白细胞抗原匹配干细胞移植术后出现移植抗宿主性疾病(GVH)。细胞毒性T淋巴细胞检测到几个不同的H-Y抗原表位,这些肽是从胞内蛋白分离出来,由主要组织相容性复合分子结合呈递在细胞表面。H-Y抗原肽与人白细胞抗原Ⅰ类和Ⅱ类分子特异结合参与免疫反应,从而影响移植结果。近年来越来越多的文献报道了H-Y抗原的相关研究,作者主要综述编码H-Y抗原的相关候选基因,并对它在疾病等方面的前景作出了一些展望。
基金This work was supported by the National Natural Science Foundation of China (Grant No.39970322) Trans-Century Training Programme Foundation for Talent under the supervision of Ministry of Education of China.
文摘The peptides mixture was prepared from tumor cells by freezing-thawing cells, precipitation by heating, followed by acidification of the solution. The activation and proliferation of mouse splenocytes by HSP70-peptide complex, formed by the binding of HSP70 and peptides in vitro, were observed, so was the specific cytotoxicity of the proliferative lymphocytes to tumor cells. The phenotypes of the proliferative lymphocytes were analyzed by a flow cytometer. BALB/c mice inoculated with H22 hepatocarcinoma cells in peritoneal cavity or hind thigh were immunized by injection with HSP70-peptides complex to observe the inhibitory effect of the immunization on tumor and lifetime of tumor-bearing mice. On the other hand, blood samples were collected from the immunized mice to check the functions of liver and kidney. The results showed that the peptides mixture from tumor cells contained tumor-specific antigen peptides which could be presented by HSP70 to activate lymphocytes in vitro, the proliferative lymphocytes were T cells which were specifically cytotoxic to tumor cells, the in vivo growth of both ascitic and solid carcinoma could be suppressed by immunization with HSP70-peptides and the lifetime of tumor-bearing mice was prolonged, the in vivo immunization with HSP70-H22-peptides had no impact on the function of mouse liver and kidney, suggesting that there was no occurrence of autoimmunity in vivo after immunization.
基金Thisprojectwassupported by a grant from the NationalNaturalScienceFoundationofChina(No.39970322)andTrans-CenturyTrainingProgramFoundation for Talent un-der the supervision of the Ministry of Education of China
文摘To investigate the inducement of cytotoxic T lym phocytes(CTL s) by antigen peptides m ixture from different leukemia cells and the cross- reaction of the m ixtures from different cell lines,antigen peptides m ixtures were prepared from different leukemia cell lines respectively and then bound with Hsp70 in vitro.Activation and proliferation of PBMC were observed after stim u- lation with different Hsp70 - peptide complexes.The ratio of CD8+ in proliferative cells was ana- lyzed by flow cytometry.The cytotoxicity of the activated PBMC to different target cells was as- sayed.The results showed that the antigen peptides from different leukemia cell lines,bound with Hsp70 ,could activate PBMC effectively,and stimulate the activated PBMC to proliferate.The proliferative PBMC had specific cytotoxicity to corresponding leukem ia cells.CD8+ cells,account- ing for a high proportion in proliferative cells,had a specific cytotoxicity to leukemia cells from which antigen peptides were prepared,suggesting that these CD8+ cells were CTL s specific to leukemia cells.CTL s activated by Hut78- peptides or Molt4 - peptides had a significantly stronger cytotoxicity to Hut78cells,Molt4 cells and Jurkat cells than that of CTL s activated by HL - 6 0 - peptides(P<0 .0 5 ) .And the cytotoxicity of CTL s activated by Hut78/ Molt4 - peptides to Jurkat cells was significantly stronger than that of CTL s activated by either Hut78- peptides or Molt4 - peptides alone(P<0 .0 5 ) .It is concluded that antigen peptides m ixtures from leukem ia cells can induce specific antitumor CTL s.There exists cross- reactivity among antigen peptides m ixtures from different cell lines of the sam e type leukemia and more cross- reactive antigen peptides could be obtained from m ore cell lines,suggesting that antigen peptides m ixture with broad antigenic spectrum could be prepared by using multiple leukemia cell lines.
基金This work was supported by grants from the National Natural Science Foundation of China (No. 39970322).
文摘Objective: To investigate the characteristics of specific antitumor immunity induced by antigen peptides mixture from T lymphocytic leukemia cells. Method: Antigen peptides mixtures were prepared from different leukemia cell lines and then bound with Hsp70 in vitro. Human peripheral blood mononuclear cells (PBMC) were cultured in vitro, and activated with Hsp70-antigen peptides. The activated PBMC was cultured continuously in vitro, and used as effector cells in vitro test of cytotoxicity to different target cells. Results: The antigen peptides from different leukemia cell lines were peptides mixture and could activate PBMC effectively if they were presented by Hsp70. The activated PBMC could proliferate in the presence of IL-2 and Hsp70-antigen peptides. The proliferative PBMC had specific cytotoxicity to leukemia cells corresponding to the antigen peptides. PBMC activated by antigen peptides from T lymphocytic leukemia cell lines could effectively kill T lymphocytic leukemia cells, and the cytotoxicity of these PBMC to T lymphocytic leukemia cells was significantly stronger than that of PBMC activated by antigen peptides from other leukemia cells (P < 0.05). PBMC activated by either Hut78-peptides or Molt 4-peptides could effectively kill Jurkat cells. And the cytotoxicity of PBMC activated by Hut78/Molt-4-peptides to Jurkat cells was significantly stronger than that of PBMC activated by either Hut78-peptides or Molt-4-peptides alone (P<0.05). Conclusion: Antigen peptides mixture from T lymphocytic leukemia cell lines can induce specific cytotoxic effect to T lymphocytic leukemia cells. There exists cross-reactivity among antigen peptides mixture from different T lymphocytic leukemia cell lines. The cross-reactivity could be amplified by blending of different antigen peptides from different T lymphocytic leukemia cell lines, suggesting that it is possible to prepare broad-spectrum antigen peptide vaccine against T lymphocytic leukemia by using multiple leukemia cell lines.
